-$0.06 Earnings Per Share Expected for NCS Multistage Holdings Inc (NCSM) This Quarter

Share on StockTwits

Analysts expect that NCS Multistage Holdings Inc (NASDAQ:NCSM) will announce earnings per share (EPS) of ($0.06) for the current quarter, Zacks reports. Four analysts have provided estimates for NCS Multistage’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.08). NCS Multistage reported earnings per share of $0.01 in the same quarter last year, which would indicate a negative year over year growth rate of 700%. The company is expected to announce its next quarterly earnings report on Thursday, March 14th.

On average, analysts expect that NCS Multistage will report full-year earnings of $0.21 per share for the current financial year, with EPS estimates ranging from $0.18 to $0.24. For the next fiscal year, analysts forecast that the firm will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.22) to $0.06. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover NCS Multistage.

NCS Multistage (NASDAQ:NCSM) last posted its earnings results on Tuesday, November 6th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.07). The business had revenue of $62.69 million for the quarter, compared to analyst estimates of $77.71 million. NCS Multistage had a return on equity of 3.10% and a net margin of 4.36%.

Several analysts have issued reports on NCSM shares. BidaskClub raised shares of NCS Multistage from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. Zacks Investment Research downgraded shares of NCS Multistage from a “hold” rating to a “sell” rating in a research report on Wednesday, October 10th. Wells Fargo & Co downgraded shares of NCS Multistage from an “outperform” rating to a “market perform” rating and set a $15.00 price objective for the company. in a research report on Monday, October 15th. TheStreet downgraded shares of NCS Multistage from a “c-” rating to a “d+” rating in a research report on Thursday, November 1st. Finally, Piper Jaffray Companies set a $10.00 target price on NCS Multistage and gave the company a “buy” rating in a research note on Thursday, November 8th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $15.21.

NCSM opened at $6.25 on Friday. The company has a market cap of $277.72 million, a P/E ratio of 31.25 and a beta of 2.19. NCS Multistage has a 1 year low of $4.90 and a 1 year high of $19.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.89 and a quick ratio of 2.89.

In other NCS Multistage news, Director Michael Mcshane bought 30,000 shares of NCS Multistage stock in a transaction dated Tuesday, November 13th. The stock was bought at an average cost of $7.36 per share, for a total transaction of $220,800.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Marty Stromquist sold 67,495 shares of the stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $7.71, for a total value of $520,386.45. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 151,721 shares of company stock valued at $1,091,923 and have sold 97,059 shares valued at $745,451. Corporate insiders own 11.70% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in NCSM. FMR LLC lifted its stake in NCS Multistage by 18.1% during the second quarter. FMR LLC now owns 4,311,228 shares of the company’s stock worth $62,642,000 after purchasing an additional 661,076 shares during the last quarter. Vanguard Group Inc lifted its stake in NCS Multistage by 20.2% in the third quarter. Vanguard Group Inc now owns 930,339 shares of the company’s stock valued at $15,360,000 after buying an additional 156,341 shares during the last quarter. Vanguard Group Inc. lifted its stake in NCS Multistage by 20.2% in the third quarter. Vanguard Group Inc. now owns 930,339 shares of the company’s stock valued at $15,360,000 after buying an additional 156,341 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in NCS Multistage by 420.4% in the third quarter. Dimensional Fund Advisors LP now owns 190,817 shares of the company’s stock valued at $3,150,000 after buying an additional 154,153 shares during the last quarter. Finally, Foundry Partners LLC lifted its stake in NCS Multistage by 15.8% in the third quarter. Foundry Partners LLC now owns 304,863 shares of the company’s stock valued at $5,033,000 after buying an additional 41,588 shares during the last quarter. Institutional investors own 97.37% of the company’s stock.

About NCS Multistage

NCS Multistage Holdings, Inc provides engineered products and support services for oil and natural gas well completions and field development strategies in the United States and internationally. The company's products include casing-installed sliding sleeves, downhole frac isolation assemblies, sand jet perforating products, spotfrac systems, ballshift sliding sleeves, airlock casing buoyancy systems, liner hanger systems, and spectrum tracer services.

Read More: Net Margin – Understanding the Different Kinds of Profit

Get a free copy of the Zacks research report on NCS Multistage (NCSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NCS Multistage (NASDAQ:NCSM)

Receive News & Ratings for NCS Multistage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NCS Multistage and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.